NCT00401804已完成2 期
Bortezomib-Doxorubicin-Dexamethasone as Treatment for Patients With Multiple Myeloma Presenting With Acute Renal Failure
Austrian Forum Against Cancer16 个研究点 分布在 3 个国家目标入组 72 人开始时间: 2006年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 72
- 试验地点
- 16
- 主要终点
- OS
研究概览
简要总结
The primary objective of the study is to evaluate the activity of BDD in subjects with acute renal failure as measured by· reversal of acute renal failureSecondary objectives· tumor response (complete and partial response)· To evaluate the safety of Bortezomib- Doxorubicin-Dexamethasone in this patient population· to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on progression free survival · to evaluate the activity of Bortezomib- Doxorubicin -Dexamethasone on overall survival
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of multiple myeloma ·
- •Acute multiple myeloma related renal failure (Diagnosis established by clinical and laboratory findings including renal biopsy - if indicated)a) Newly diagnosed patients:Decrease of GFR to < 50ml/minb) Previously treated patients with GFR of ≥ 60ml/min within last 4 weeks: decrease in GFR > 25% and to < 60ml / min,concomitantly with either increase in paraproteins (>25%) and/or decrease in hemoglobin ≥ 2 g/dl (within 4 weeks) and/or increase in bone marrow plasma infiltration and/or increase in number of bone lesions and/or hypercalcaemia (Ca > 11.5 mg/dl or 2.8 mmol/l) as signs of disease progression·
- •Age > 20 years·
- •ECOG performance status of ≤ 3.·
- •Platelet count > 50.000/µl·
- •WBC > 2000/µl·
- •Total bilirubin < 1.5 x upper limit of normal,
- •AST, ALT < 2.5 x upper limit of normal·
- •International Normalized Ratio (INR) < 1.5; APTT < 1.5 x upper limit of normal·
- •Fertile women and men of childbearing potential (<2 years after last menstruation in women) must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)· Negative serum or urine β-HCG pregnancy test at screening for subjects of child-bearing potential·
- •Patient's written informed consent
排除标准
- •History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years.·
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.·
- •Evidence of CNS involvement or spinal cord compression.·
- •Neuropathy Grade ≥ 2·
- •A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drug.·
- •NYHA Status > 2, i.e. clinically significant cardiac disease, (congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmias, and arterial hypertension not well controlled with medication) or myocardial infarction within the last 6 months ·
- •Evidence of bleeding diathesis or coagulopathy·
- •Serious, non-healing wound or ulcer·
- •Evidence of any severe active acute or chronic infection.·
- •Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or patient at high risk from treatment complications·
- •Patient is known to be HIV-positive, Hbs-antigen positive or HCV-RNA-positive·
- •Pregnant women or nursing mothers·
- •Have received bortezomib within 4 weeks before enrollment·
- •Half body irradiation < 28 days before enrollment·
- •Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
结局指标
主要结局
OS
次要结局
- OR
研究者
研究点 (16)
Loading locations...
相似试验
已完成
不适用
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisLight Chain Deposition Disease (LCDD or MIDD)Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)Monoclonal Immunoglobulin Deposition Disease (MIDD)AmyloidosisNCT01383759Memorial Sloan Kettering Cancer Center20
已完成
2 期
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseMultiple MyelomaNCT00335348Peter MacCallum Cancer Centre, Australia101
终止
2 期
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's LymphomaHodgkin DiseaseNCT00148018University of Cologne37
已完成
2 期
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple MyelomaMultiple MyelomaNCT00872521Janssen-Cilag Pty Ltd107
进行中（未招募）
不适用
Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure - BDDThe occurrence of renal failure is an emergency situation in patients with multiple myeloma. A fast active relatively, non-toxic protocol seems presently the best option for attempts to reverse renal insufficiency. Therefore we have designed a small Phase 2 trial with a Bortezomib containing regimen, which intends to revert renal failure in a greater proportion of patients compared to conventional regimens.EUCTR2005-003001-85-CZAustrian Forum against Cancer50